Nuvation Bio (NUVB) Other Non-Current Assets (2023 - 2026)
Nuvation Bio (NUVB) posted quarterly Other Non-Current Assets of $3.8 million for Q1 2026, down 42.2% year-over-year from $6.6 million in Q1 2025, and down 49.73% quarter-over-quarter from $7.6 million in Q4 2025.
Nuvation Bio (NUVB) Other Non-Current Assets (2023 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Other Non-Current Assets for 4 consecutive years, with $3.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 42.2% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (down 42.2% YoY), while the FY2025 annual figure was $7.6 million, up 12.51% from the prior year.
- Other Non-Current Assets declined to $3.8 million in Q1 2026 per NUVB's latest filing, from $7.6 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $7.6 million in Q4 2025 and bottomed at $480000.0 in Q3 2024.
- Historically, Other Non-Current Assets has averaged $3.9 million across 4 years, with a median of $3.8 million in 2026.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets jumped 1454.58% — and 2026, when it slumped 42.2%.
- Nuvation Bio's Other Non-Current Assets stood at $587000.0 in 2023, then jumped by 1051.79% to $6.8 million in 2024, then climbed by 12.51% to $7.6 million in 2025, then sank by 49.73% to $3.8 million in 2026.
- Business Quant data shows NUVB's Other Non-Current Assets at $3.8 million in Q1 2026, $7.6 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.82 Mn |
| Mar 31, 2026 | 3.82 Mn |
| Dec 31, 2025 | 7.61 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Jun 30, 2025 | 6.62 Mn |
| Mar 31, 2025 | 6.62 Mn |
| Dec 31, 2024 | 6.76 Mn |
| Sep 30, 2024 | 480,000.00 |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Dec 31, 2023 | 587,000.00 |
| Sep 30, 2023 | 587,000.00 |